Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer.

Autor: Afsar CU; Acıbadem Bakırkoy Hospital, Department of Internal Medicine and Medical Oncology, Medical Faculty, Acıbadem Mehmet Ali Aydınlar University, Zeytinlik Mah. Halit Ziya Usaklıgil Cad. No: 1, Bakırkoy, 34140 Istanbul, Turkey. cigdem.afsar@acibadem.edu.tr., Karabulut M; Department of General Surgery, Bakırkoy Dr Sadi Konuk Education and Research Hospital, Health Sciences University, 34147 Istanbul, Turkey. mehmetkarabulut@hotmail.com., Karabulut S; Department of Medical Oncology, Institute of Oncology, Istanbul University, 34452 Fatih/Istanbul, Turkey. drsenemkarabulut@gmail.com., Ozal ST; Department of Radiology, Bakırkoy Dr Sadi Konuk Education and Research Hospital, Health Sciences University, 34147 Istanbul, Turkey. safiyeozal@gmail.com., Cikot M; Department of General Surgery, Bakırkoy Dr Sadi Konuk Education and Research Hospital, Health Sciences University, 34147 Istanbul, Turkey. mehmet_mac@hotmail.com., Serilmez M; Department of Basic Oncology, Institute of Oncology, Istanbul University, 34452 Istanbul, Turkey. serilmez55@hotmail.com., Tas F; Department of Medical Oncology, Institute of Oncology, Istanbul University, 34452 Fatih/Istanbul, Turkey. ftas@yahoo.com.
Jazyk: angličtina
Zdroj: Biomolecules [Biomolecules] 2018 Dec 10; Vol. 8 (4). Date of Electronic Publication: 2018 Dec 10.
DOI: 10.3390/biom8040169
Abstrakt: Introduction: Pancreatic cancer (PC) is a lethal malignancy. Various diagnostic, predictive, and prognostic biomarkers have been evaluated. This study was conducted to investigate the serum levels of neural precursor cell expressed developmentally downregulated protein 9 (NEDD9) in patients with PC and the relationship between tumor progression and known prognostic parameters.
Materials and Methods: Serum samples were obtained on first admission before any treatment. Serum NEDD9 levels were determined using enzyme-linked immunosorbent assay (ELISA). Age- and sex-matched healthy controls were included in the analysis.
Results: In a three year period, 32 patients with a pathologically-confirmed diagnosis of PC were enrolled in this study. The median age at diagnosis was 61 years, range 38 to 84 years; the majority of the patients in the group were men ( n = 20, 62.5%). The tumor was located in the head of pancreas in 21 (65.6%) patients. Forty-one percent of 17 metastatic patients who received palliative CTx (chemotherapy) were CTx-responsive. The baseline serum NEDD9 levels were significantly higher in patients with PA than in the control group ( p = 0.03). Median OS of the whole group were 27 ± 7.3 weeks. Alcohol intake, performance status, and LDH levels were found to be significant prognostic factors ( p = 0.006, p < 0.001, and p < 0.001, respectively). However, serum NEDD9 levels had no significantly effect on progression free survival (PFS) and overall survival (OS) ( p = 0.71 and p = 0.58, respectively).
Conclusions: NEDD9 is identified as a secretory biomarker for PC but it has no prognostic role.
Competing Interests: The authors declare no conflicts of interest.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje